Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,900,404
  • Shares Outstanding, K 106,706
  • Annual Sales, $ 7,863 M
  • Annual Income, $ 2,116 M
  • 60-Month Beta 0.32
  • Price/Sales 6.98
  • Price/Cash Flow 21.23
  • Price/Book 5.44
Trade REGN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 7.11
  • Number of Estimates 1
  • High Estimate 7.11
  • Low Estimate 7.11
  • Prior Year 6.58
  • Growth Rate Est. (year over year) +8.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
497.12 +0.35%
on 12/03/20
596.80 -16.41%
on 11/05/20
-58.35 (-10.47%)
since 11/03/20
3-Month
497.12 +0.35%
on 12/03/20
619.97 -19.54%
on 10/05/20
-78.56 (-13.61%)
since 09/03/20
52-Week
328.13 +52.03%
on 01/31/20
664.64 -24.95%
on 07/20/20
+130.03 (+35.26%)
since 12/03/19

Most Recent Stories

More News
Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US

With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).

REGN : 498.84 (-1.25%)
GILD : 60.86 (-0.44%)
INCY : 82.90 (+0.77%)
LLY : 144.11 (-0.72%)
Scott+Scott Attorneys at Law LLP Continues Investigation of Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty - REGN

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, continues its investigation whether certain directors and officers of Regeneron Pharmaceuticals,...

REGN : 498.84 (-1.25%)
5 Stocks in Dow ETF That Powered the Best Month Since 1987

Amid rising COVID-19 cases, the Dow Jones wrapped up its best month in more than 30 years after hitting the major milestone of 30,000 for the first time last week.

BA : 237.20 (+5.96%)
GS : 235.47 (-0.92%)
REGN : 498.84 (-1.25%)
AZN : 52.78 (-1.14%)
CVX : 89.80 (-0.08%)
PFE : 40.09 (-1.74%)
AXP : 123.12 (+0.65%)
DIS : 153.24 (-0.24%)
MRNA : 157.26 (+9.97%)
DIA : 300.06 (+0.29%)
Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion

Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.

REGN : 498.84 (-1.25%)
SNY : 50.11 (-1.01%)
BAYRY : 14.5300 (unch)
HALO : 39.23 (-3.52%)
Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting

, /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a webcast on Monday, December 7, 2020 at . Management will discuss data presented at the American Society of Hematology...

REGN : 498.84 (-1.25%)
Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

and , /PRNewswire/ --

REGN : 498.84 (-1.25%)
RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US

RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.

REGN : 498.84 (-1.25%)
INCY : 82.90 (+0.77%)
LLY : 144.11 (-0.72%)
RDHL : 8.63 (-2.15%)
Energy on Track for Its Best Month Ever: 5 ETF, Stock Winners

The S&P 500 Energy Index is on track for the best month ever, gaining nearly 40%.

RIG : 2.03 (-2.87%)
REGN : 498.84 (-1.25%)
AZN : 52.78 (-1.14%)
PFE : 40.09 (-1.74%)
MRNA : 157.26 (+9.97%)
SM : 4.37 (+3.80%)
FCEL : 7.38 (+1.93%)
XES : 42.49 (+0.85%)
IEZ : 10.87 (+1.49%)
OIH : 150.66 (+1.67%)
PXJ : 2.85 (+1.40%)
RYE : 30.74 (+2.06%)
ALTM : 41.01 (+4.48%)
FTSI : 18.27 (-0.98%)
Is Regeneron Pharmaceuticals (REGN) a Worthy Stock Now?

Let's see if Regeneron Pharmaceuticals (REGN) stock is a good choice for value-oriented investors right now from multiple angles.

REGN : 498.84 (-1.25%)
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

REGN : 498.84 (-1.25%)
LLY : 144.11 (-0.72%)
EQ : 4.93 (-2.18%)
VIR : 31.50 (+1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 514.25
1st Resistance Point 506.55
Last Price 498.84
1st Support Level 494.13
2nd Support Level 489.41

See More

52-Week High 664.64
Fibonacci 61.8% 536.09
Last Price 498.84
Fibonacci 50% 496.38
Fibonacci 38.2% 456.67
52-Week Low 328.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar